BioLife Solutions, Inc. (BLFS) Reports Q3 Loss, Tops Revenue Estimates

Core Insights - BioLife Solutions, Inc. reported a quarterly loss of $0.02 per share, outperforming the Zacks Consensus Estimate of a loss of $0.09, and showing improvement from a loss of $0.67 per share a year ago [1] - The company achieved revenues of $30.57 million for the quarter ended September 2024, exceeding the Zacks Consensus Estimate by 21.98%, although this represents a decline from $33.33 million in the same quarter last year [2] - BioLife Solutions has surpassed consensus EPS estimates for four consecutive quarters, indicating a positive trend in earnings performance [2] Financial Performance - The quarterly report resulted in an earnings surprise of 77.78%, with a previous quarter's surprise of 57.14% when the loss was expected to be $0.14 per share but was reported as $0.06 [1] - The current consensus EPS estimate for the upcoming quarter is -$0.07 on revenues of $26.02 million, and for the current fiscal year, it is -$0.36 on revenues of $111.18 million [7] Market Position - BioLife Solutions shares have increased approximately 63.7% since the beginning of the year, significantly outperforming the S&P 500's gain of 25.8% [3] - The Zacks Industry Rank places the Medical - Products sector in the top 34% of over 250 Zacks industries, suggesting a favorable industry outlook [8] Future Outlook - The sustainability of the stock's price movement will depend on management's commentary during the earnings call and the trends in earnings estimate revisions [3][4] - Current estimate revisions for BioLife Solutions are unfavorable, resulting in a Zacks Rank 4 (Sell), indicating expectations of underperformance in the near future [6]